Merck & Co Inc

Change company Symbol lookup

Select an option...

MRK Merck & Co Inc

PAYX Paychex Inc

PYR Pyrogenesis Canada Inc

PM Philip Morris International Inc

GWAV Greenwave Technology Solutions Inc

SLNO Soleno Therapeutics Inc

VRPX Virpax Pharmaceuticals Inc

FDCFF Forum Energy Metals Corp

AFMD Affimed NV

ARVN Arvinas Inc

Go

Merck (MRK) closed the most recent trading day at $103.94, moving -1.38% from the previous trading session.(Zacks)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Merck & Co. Inc. (MRK) shed 1.38% to $103.94 Wednesday, on what proved to be an all-around mixed trading session for the...(MarketWatch)

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Exxon Mobil Corp. (XOM) and Merck & Co., Inc. (MRK).(Zacks)

By Ciara Linnane Study published in Nature says molnupiravir may allow mutated viruses to spread An antiviral drug that was granted an emergency use authorization by the U.S. Food and Drug Administration in December 2021 may be...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Merck & Co. Inc. (MRK) shed 0.43% to $105.39 Tuesday, on what proved to be an all-around rough trading session for the stock...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Merck & Co. Inc. (MRK) slipped 0.47% to $105.84 Monday, on what proved to be an all-around positive trading session for the...(MarketWatch)

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.(Zacks)

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%. (Zacks)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of 3M and Merck are trading lower Monday morning, sending the Dow Jones Industrial Average into negative territory. Shares of 3M...(MarketWatch)

Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.(Zacks)

Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.(Zacks)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Merck & Co. Inc. (MRK) shed 0.37% to $106.34 Friday, on what proved to be an all-around grim trading session for the stock...(MarketWatch)

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC. (Zacks)

The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.(Zacks)

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (MarketWatch)

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (MarketWatch)

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (MarketWatch)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple...(BusinessWire)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in collaboration with Seagen and Astellas, evaluating...(BusinessWire)

Style Box ETF report for SCHD(Zacks)